|
1
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kobayashi H, Tanisaka K, Kondo N, Mito Y,
Koezuka M, Yokouchi H, Higashiyama M, Kodama K, Doi O, Yamada M, et
al: Development of new in vitro chemosensitivity test using
collagen gel droplet embedded culture and its clinical usefulness.
Gan To Kagaku Ryoho. 22:1933–1939. 1995.(In Japanese). PubMed/NCBI
|
|
3
|
Kobayashi H, Tanisaka K, Doi O, Kodama K,
Higashiyama M, Nakagawa H, Miyake M, Taki T, Hara S, et al: An in
vitro chemosensitivity test for solid human tumors using collagen
gel droplet embedded cultures. Int J Oncol. 11:449–455.
1997.PubMed/NCBI
|
|
4
|
Naitoh H, Yamamoto H, Murata S, Kobayashi
H, Inoue K and Tani T: Stratified phase II trial to establish the
usefulness of the collagen gel droplet embedded culture-drug
sensitivity test (CD-DST) for advanced gastric cancer. Gastric
Cancer. 17:630–637. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ochiai T, Nishimura K, Watanabe T,
Kitajima M, Nakatani A, Inou T, Washio M, Sakuyama N, Sato T,
Kishine K, et al: Individualized chemotherapy for colorectal cancer
based on the collagen gel droplet-embedded drug sensitivity test.
Oncol Lett. 4:621–624. 2012.PubMed/NCBI
|
|
6
|
Mekata E, Sonoda H, Shimizu T, Tatsuta T,
Yamaguchi T, Endo Y and Tani T: Clinical predictive value of in
vitro anticancer drug sensitivity test for the therapeutic effect
of adjuvant chemotherapy in patients with stage II–III colorectal
cancer. Mol Clin Oncol. 1:763–767. 2013.PubMed/NCBI
|
|
7
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sakuma K, Tanaka A and Mataga I: Collagen
gel droplet-embedded culture drug sensitivity testing in squamous
cell carcinoma cell lines derived from human oral cancers: Optimal
contact concentrations of cisplatin and fluorouracil. Oncol Lett.
12:4643–4650. 2016.PubMed/NCBI
|
|
9
|
Takamura Y, Kobayashi H, Taguchi T,
Motomura K, Inaji H and Noguchi S: Prediction of chemotherapeutic
response by collagen gel droplet embedded culture-drug sensitivity
test in human breast cancers. Int J Cancer. 98:450–455. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yoshino T, Hasegawa Y, Takahashi S, Monden
N, Homma A, Okami K, Onozawa Y, Fujii M, Taguchi T, de Blas B, et
al: Platinum-based chemotherapy plus cetuximab for the first-line
treatment of Japanese patients with recurrent and/or metastatic
squamous cell carcinoma of the head and neck: Results of a phase ii
trial. Jpn J Clin. 43:524–531. 2013. View Article : Google Scholar
|
|
11
|
Salmon SE, Mamburger AW, Soehnlen B, Durie
BG, Alberts DS and Moon TE: Quantitation of differential
sensitivity of human tumor stem cells to anticancer drugs. N Engl J
Med. 298:1321–1327. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tanigawa N, Kern DH, Hisaka Y and Morton
DL: Rapid assay for evaluating the chemosensitivity of human tumors
in soft agar culture. Cancer Res. 42:2159–2164. 1982.PubMed/NCBI
|
|
13
|
Kern DH, Dogemullar CR, Kennedy MC,
Hildebrand-Zanki SU, Tanigawa N and Sondak VK: Development of
miniaturized, improved nucleic acid precursor incorporation assay
for chemosensitivity testing of human solid tumors. Cancer Res.
45:5436–5441. 1985.PubMed/NCBI
|
|
14
|
Araki Y, lsomoto H, Matsumoto A, Kaibara
A, Yasunaga M, Hayashi K, Yatsugi H and Yamauchi K: An in vitro
chemosensitivity test for colorectal cancer using collagen-gel
droplet embedded cultures. Kurume Med J. 46:163–166. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kawamura M, Inoue Y, Oyama T and Kobayashi
K: Chemosensitivity test for unresectable non-small cell lung
cancer. Nihon Geka Gakkai Zasshi. 103:229–232. 2002.(In Japanese).
PubMed/NCBI
|
|
16
|
Prewett M, Rockwell P, Rose C and
Goldstein N: Anti-tumor and cell cycle responses in KB cells
treated with a chimeric anti-EGFR monoclonal antibody in
combination with cisplatin. Int J Oncol. 9:217–224. 1996.PubMed/NCBI
|
|
17
|
Huang S, Armstrong EA, Benavente S,
Chinnaiyan P and Harari PM: Dual-agent molecular targeting of the
epidermal growth factor receptor (EGFR): Combining anti-EGFR
antibody with tyrosine kinase inhibitor. Cancer Res. 64:5355–5362.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kimura H, Sakai K, Arao T, Shimoyama T,
Tamura T and Nishio K: Antibody- dependent cellular cytotoxicity of
cetuximab against tumor cells with wild-type or mutant epidermal
growth factor receptor. Cancer Sci. 98:1275–1280. 2007. View Article : Google Scholar : PubMed/NCBI
|
